GSK RSV vaccine is still 43% effective against severe disease after third year

Primary tabs

Tue, 2024-10-08 10:48 — mike kraft

GSK RSV shot 43% effective against severe disease in third yearhttps://

Oct 8 (Reuters) - GSK (GSK.L) , opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.

That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial. The trial initially enrolled about 25,000 volunteers in 17 countries.

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?: